Revvity Inc. (NYSE:RVTY) Given Average Rating of “Hold” by Analysts

Shares of Revvity Inc. (NYSE:RVTY) have been assigned a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $113.9091.

Several brokerages have weighed in on RVTY. Bank of America cut Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective on the stock. in a research note on Monday, December 15th. The Goldman Sachs Group initiated coverage on shares of Revvity in a report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 target price for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Revvity in a research report on Monday, December 29th. Wells Fargo & Company upped their price objective on shares of Revvity from $102.00 to $107.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Finally, Evercore ISI reiterated an “outperform” rating on shares of Revvity in a research note on Monday, January 5th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. EdgePoint Investment Group Inc. grew its holdings in shares of Revvity by 26.3% in the third quarter. EdgePoint Investment Group Inc. now owns 8,574,280 shares of the company’s stock valued at $751,536,000 after purchasing an additional 1,784,620 shares in the last quarter. Invesco Ltd. raised its stake in Revvity by 15.7% during the third quarter. Invesco Ltd. now owns 2,553,515 shares of the company’s stock valued at $223,816,000 after purchasing an additional 346,313 shares in the last quarter. UBS Group AG lifted its position in Revvity by 22.3% during the third quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock valued at $191,034,000 after purchasing an additional 397,160 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Revvity by 39.0% during the third quarter. Dimensional Fund Advisors LP now owns 2,125,957 shares of the company’s stock valued at $186,307,000 after purchasing an additional 596,436 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Revvity by 127.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,751,612 shares of the company’s stock worth $171,921,000 after buying an additional 980,142 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Stock Performance

Shares of RVTY opened at $116.64 on Friday. The firm has a market capitalization of $13.22 billion, a P/E ratio of 58.61, a P/E/G ratio of 3.57 and a beta of 1.05. Revvity has a 52 week low of $81.36 and a 52 week high of $128.29. The stock has a 50 day moving average price of $102.18 and a two-hundred day moving average price of $95.02. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 1.75.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, October 27th. The company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.04. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The company had revenue of $698.95 million for the quarter, compared to analyst estimates of $699.75 million. During the same quarter last year, the company earned $1.28 earnings per share. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS. Equities analysts forecast that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity declared that its board has initiated a stock repurchase plan on Monday, October 27th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to repurchase up to 8.7% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.